Related Experiment Video
Updated: Mar 7, 2026

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus)
Kimberley A Phillips1, Corinna N Ross2, Jennifer Spross3
1Department of Psychology, Trinity University, San Antonio TX, United States; Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, United States.
Abstract:
Parkinson's disease is a chronic neurodegenerative disorder with the core motor features of resting tremor, bradykinesia, rigidity, and postural instability. Non-motor symptoms also occur, and include cognitive dysfunction, mood disorders, anosmia (loss of smell), and REM sleep disturbances. As the development of medications and other therapies for treatment of non-motor symptoms is ongoing, it is essential to have animal models that aid in understanding the neural changes underlying non-motor PD symptoms and serve as a testing ground for potential therapeutics. We investigated several non-motor symptoms in 10 adult male marmosets using the MPTP model, with both the full (n=5) and partial (n=5) MPTP dosing regimens. Baseline data in numerous domains were collected prior to dosing; assessments in these same domains occurred post-dosing for 12 weeks. Marmosets given the partial MPTP dose (designed to mimic the early stages of the disease) differed significantly from marmosets given the full MPTP dose in several ways, including behavior, olfactory discrimination, cognitive performance, and social responses. Importantly, while spontaneous recovery of PD motor symptoms has been previously reported in studies of MPTP monkeys and cats, we did not observe recovery of any non-motor symptoms. This suggests that the neurochemical mechanisms behind the non-motor symptoms of PD, which appear years before the onset of symptoms, are independent of the striatal dopaminergic transmission. We demonstrate the value of assessing a broad range of behavioral change to detect non-motor impairment, anosmia, and differences in socially appropriate responses, in the marmoset MPTP model of early PD.
Insights
This study used the MPTP model in marmosets to investigate Parkinson's disease (PD) non-motor symptoms. Non-motor deficits did not recover, suggesting they are independent of dopaminergic transmission.
Area of Science:
- Neuroscience
- Primatology
- Pharmacology
Background:
- Parkinson's disease (PD) presents with motor and non-motor symptoms, including cognitive and olfactory deficits.
- Developing effective treatments for non-motor PD symptoms requires robust animal models.
- The MPTP-induced primate model offers a valuable platform for studying PD pathogenesis and therapeutics.
Purpose of the Study:
- To investigate non-motor symptoms in marmosets using the MPTP model.
- To compare the effects of full and partial MPTP dosing regimens on non-motor PD features.
- To assess the potential for recovery of non-motor symptoms in this model.
Main Methods:
- Ten adult male marmosets were administered either a full or partial MPTP dose.
- Comprehensive behavioral, olfactory, cognitive, and social assessments were conducted pre- and post-dosing for 12 weeks.
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) was used to induce Parkinsonism.
Main Results:
- Marmosets receiving partial MPTP doses showed significant differences in behavior, olfactory discrimination, cognition, and social responses compared to those receiving full doses.
- No recovery of non-motor symptoms was observed during the 12-week assessment period.
- The study identified distinct non-motor impairments, including anosmia and altered social behaviors.
Conclusions:
- Non-motor symptoms in the marmoset MPTP model appear independent of striatal dopaminergic transmission.
- The findings suggest that non-motor PD symptoms may arise from mechanisms distinct from those driving motor deficits.
- Assessing a wide range of behavioral changes is crucial for detecting non-motor impairments in PD models.

